atorvastatin has been researched along with Drug Associated Myopathies in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bašić-Jukić, N; Sabljić, Z | 1 |
| Lao, VWN; Lau, WY; Lee, KF; Mak, MWH; Wong, VTL; Yip, HLK | 1 |
| Hoffmann, TJ; Iribarren, C; Krauss, RM; Lu, B; Medina, MW; Oni-Orisan, A; Risch, N; Seraydarian, M; Sun, L | 1 |
3 other study(ies) available for atorvastatin and Drug Associated Myopathies
| Article | Year |
|---|---|
Toxic myopathy and liver damage caused by concomitant therapy with remdesivir, atorvastatin, ezetimibe, and tacrolimus in a renal transplant patient with recently treated SARS-CoV-2 induced pneumonia: A case report.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Atorvastatin; COVID-19 Drug Treatment; Ezetimibe; Humans; Kidney Transplantation; Liver; Myotoxicity; Pneumonia; SARS-CoV-2; Tacrolimus | 2022 |
Immune-mediated necrotising myopathy is a rare statin-associated adverse effect: a case report.
Topics: Atorvastatin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Female; Gliclazide; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Middle Aged; Myotoxicity; Vildagliptin | 2020 |
Effect of SLCO1B1 T521C on Statin-Related Myotoxicity With Use of Lovastatin and Atorvastatin.
Topics: Aged; Aged, 80 and over; Aging; Atorvastatin; Case-Control Studies; Female; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Lovastatin; Male; Muscular Diseases; Myotoxicity; Phenotype; Polymorphism, Single Nucleotide | 2021 |